-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $42 Price Target

Benzinga·06/17/2025 16:43:51
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $42 price target.